Allarity Therapeutics, Inc. ( (ALLR) ) has provided an update.
Allarity Therapeutics has announced a significant milestone in its Phase 2 clinical trial for stenoparib, a novel treatment for advanced ovarian cancer, with two patients surpassing one year of therapy. These patients, pre-selected using Allarity’s Drug Response Predictor for their likely positive response to the drug, have shown durable clinical benefits, including complete response and long-term disease stability. The company is optimistic about stenoparib’s unique mechanism of action and is actively pursuing its advancement towards regulatory approval, with further updates expected in the near future.
Learn more about ALLR stock on TipRanks’ Stock Analysis page.
